ReviewJournal of diabetes and metabolic disorders2022
Tryptophan and serotonin levels as potent biomarkers in diabetes mellitus complications: a new approach of diagnostic role.
Review in Journal of diabetes and metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 14 citations in OpenAlex.
- Review
- Analysis of Serum Serotonin by High-Performance Liquid Chromatography-Tandem Mass Spectrometry Using Online Solid-Phase Extraction.Bulletin of experimental biology and medicine · 2025Article
- Serotonin and Interleukin 10 Can Influence the Blood and Urine Viscosity in Gestational Diabetes Mellitus and Pregnancy-Specific Urinary Incontinence.International journal of molecular sciences · 2023Article
- Exploring the Role of Serotonin as an Immune Modulatory Component in Cardiovascular Diseases.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Alterations in the serotonergic system were verified to act a role in the pathogenesis of altered neurological and psychiatric diseases. In recent years, Tryptophan (Trp) and serotonin (5-HT) levels have been considered potent biomarkers of diabetes mellitus (DM). Method: The different Trp metabolism may also play roles in the pathogenesis of DM and mounting risk of complications. The whole blood (WB) 5-HT level was mainly lower among diabetic patients compared to others. That is mostly derived from a lower platelet concentration of 5-HT in these patients. Results: Indeed, 5-HT level can be considered a potent biomarker for early detection of DM complications. Besides, it was proved that outside the digestive and central nervous systems, 5-HT was discovered in beta cells, and scientists have been attempting to realize its mechanism of action ever since. Towards to end, the determination methods, biomarker's role, and approaches of 5-HT and Trp levels were thoroughly investigated in both healthy and diabetic patients with or without complications. Moreover, the association between insulin and 5-HT has been specifically discussed. Conclusions: Our study concluded that Trp and 5-HT levels could be exclusively applied for early diagnosis of DM complications as well as many other complications. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.